Apyx Medical (NASDAQ:APYX) Raised to Buy at BTIG Research

Apyx Medical (NASDAQ:APYX) was upgraded by stock analysts at BTIG Research from a “neutral” rating to a “buy” rating in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a $6.00 price objective on the stock. BTIG Research’s target price would suggest a potential upside of 73.91% from the company’s previous close.

Other research analysts have also issued research reports about the company. Wall Street Zen raised Apyx Medical to a “hold” rating in a report on Saturday, November 22nd. Roth Mkm began coverage on shares of Apyx Medical in a research report on Monday, December 15th. They set a “buy” rating and a $6.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a report on Monday, December 29th. Zacks Research raised shares of Apyx Medical to a “hold” rating in a report on Wednesday, December 17th. Finally, Citizens Jmp raised Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 price objective on the stock in a report on Wednesday, November 12th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $6.67.

Apyx Medical Stock Performance

Shares of APYX stock opened at $3.45 on Wednesday. The stock’s 50-day moving average price is $3.74 and its 200 day moving average price is $3.31. The company has a quick ratio of 3.61, a current ratio of 4.44 and a debt-to-equity ratio of 5.69. The stock has a market capitalization of $131.93 million, a PE ratio of -9.58 and a beta of 1.61. Apyx Medical has a 52-week low of $0.76 and a 52-week high of $4.50.

Apyx Medical (NASDAQ:APYX) last posted its quarterly earnings data on Tuesday, March 10th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. Apyx Medical had a negative return on equity of 151.01% and a negative net margin of 30.35%.The company had revenue of $19.16 million during the quarter, compared to analysts’ expectations of $19.12 million. As a group, equities research analysts forecast that Apyx Medical will post -0.68 EPS for the current year.

Institutional Investors Weigh In On Apyx Medical

Several institutional investors and hedge funds have recently made changes to their positions in the business. Kingsview Wealth Management LLC increased its holdings in Apyx Medical by 9.4% during the 2nd quarter. Kingsview Wealth Management LLC now owns 191,597 shares of the company’s stock valued at $431,000 after acquiring an additional 16,502 shares in the last quarter. Fisher Asset Management LLC purchased a new stake in shares of Apyx Medical in the second quarter valued at about $34,000. Nantahala Capital Management LLC lifted its holdings in shares of Apyx Medical by 2.5% in the second quarter. Nantahala Capital Management LLC now owns 3,338,048 shares of the company’s stock valued at $7,511,000 after purchasing an additional 80,000 shares in the last quarter. Osaic Holdings Inc. acquired a new stake in shares of Apyx Medical in the second quarter valued at approximately $50,000. Finally, Salem Investment Counselors Inc. purchased a new position in shares of Apyx Medical during the 3rd quarter worth approximately $97,000. 55.33% of the stock is currently owned by hedge funds and other institutional investors.

Key Apyx Medical News

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: Q4 results: Apyx reported EPS of ($0.03) vs. consensus ($0.06) and revenue of $19.16M (vs. $19.12M expected) — the beat supports near‑term sentiment and shows improving top‑line execution. Apyx Medical Corp (APYX) Q4 2025 Earnings Call Highlights
• Positive Sentiment: FY‑2026 revenue guidance raised: management guided revenue to $57.5M–$58.5M, above the consensus ~$55.9M — this upward guidance is the main constructive catalyst for the stock today. Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Growth driver: the company reiterated a 9%–11% revenue growth target for 2026 and cited acceleration of the AYON Body Contouring System launch — investors may view product momentum as evidence that guidance is achievable. Apyx Medical outlines 9%–11% revenue growth target for 2026 as AYON launch
• Neutral Sentiment: Analyst/press coverage: earnings breakdowns and summaries (Benzinga, MarketBeat coverage and the company’s press release/conference call transcript) are available for investors to review management commentary and model impacts. Earnings Breakdown: Apyx Medical Q4 Company Press Release / Call Transcript
• Negative Sentiment: Profitability remains a concern: Apyx reported a negative net margin (~‑30%) and very negative ROE (~‑151%), indicating continued losses and execution risks despite revenue growth. Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Short interest moved higher in late February (173,573 shares, +22.3% vs. prior period; ~0.5% of float, ~2.7 days to cover). Elevated shorting can add volatility and represents a potential headwind if negative sentiment persists. (Data point reported in filings/market feeds.)
• Neutral Sentiment: Data anomalies on short interest in early March (entries showing 0 shares) appear inconsistent — treat those figures as unreliable until exchanges/custodians reconcile the reports.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.